Clinical trial · Observational
Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
NCT02106611CI-TRIAL-00103030completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will test whether cardiac MRI can improve early detection of Hodgkin lymphoma associated heart disease compared to a stress echocardiogram. By doing both stress echocardiography and cardiac MRI, we will compare the ability of the two tests to detect heart disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma Survivor | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinical Assessment | Other | — | UNRESOLVED |
| Stress cardiac MRI | Procedure | — | UNRESOLVED |
| Stress echocardiogram | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Hodgkin Lymphoma Survivor
- description
- This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment.
- interventionNames
- Other: Clinical Assessment
- Procedure: Stress cardiac MRI
- Procedure: Stress echocardiogram
Primary outcomes (1)
- measure
- compare the prevalence of cardiac injury
- timeFrame
- 2 years
- description
- detected by cardiac MRI to that detected by stress echocardiography among a broadly representative cohort of Hodgkin lymphoma survivors.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Classical or nodular lymphocyte predominant HL treated at Memorial Sloan-Kettering Cancer Center. * Age ≥ 18 years * Treatment for HL that included mediastinal RT at initial diagnosis or relapse. * ≥ 5 years from last HL treatment. Exclusion Criteria: * Primary HL diagnosis prior to 1980. * Additional mediastinal RT or subsequent cardiotoxic systemic therapy for secondary malignant neoplasm. * Known CAD/CHF (defined as documented myocardial infarction, cardiac revascularization, angiographic obstructive CAD, or decreased LV function \[EF \< 55%\] during prior clinical care). * Contraindication to MRI (i.e. pacemakers, defibrillators, or aneurysm clips, or other implanted ferromagnetic objects), gadolinium (i.e. known hypersensitivity to gadolinium, advanced renal insufficiency as defined by glomerular filtration rate \<30 ml/min/1.73m\^2). * Contraindication to exercise stress testing other than the above (i.e. unstable angina or severe valvular stenosis).
References
Publications (0)
Data not yet available
No reference posted for this study.